poisar

Economy · News reference

S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today

Piero Cingari

Crude near $98 pushes the 10-year Treasury yield above 4.8% for the first time since 2023, hammering the Dow as traders price a Fed rate hike next week.

More economy newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AAPLAMGNBECRWVDIAFOURFRMIGDDYGWREIBBIGVINTCITBIWMLITENVDANVSORCLPATHPBWQCOMQQQROIVSMHSYKTANTSLAVOOXLEXLFXLKXLREXLUXLVXMEXOPXRT
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Sara Appino

    Applied Materials vs. Broadcom: Which Semiconductor Stock Is a Better Buy in 2026?

    The article compares Applied Materials and Broadcom as semiconductor investment options for 2026. Applied Materials provides chip manufacturing equipment with $28.4B in FY2025 revenue and strong free cash flow of $5.7B, but faces customer concentration risks and export control challenges. Broadcom, with $63.9B in FY2025 revenue and $26.9B in free cash flow, is recommended as the better buy due to its dominant AI accelerator business with locked-in commitments from major tech companies and deeper, harder-to-replicate hyperscaler relationships.

    AMATAVGOTSMAAPL
  4. Keithen Drury

    Warren Buffett's Successor Has Billions Invested in These 2 Tech Stocks. Here's the Better Buy.

    The article compares Apple and Alphabet as major holdings in Berkshire Hathaway's portfolio, analyzing their divergent AI strategies. Alphabet has heavily invested in AI across its products and infrastructure, while Apple has taken a measured approach. Despite Apple's higher valuation, the author recommends Alphabet as the better buy due to its stronger AI positioning and cheaper valuation based on operating income metrics.

    AAPLGOOGGOOGLGOOGMGOOGN
  5. Thomas Niel

    Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?

    Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space.

    RPRXREGNIONSNVSAMGN
  6. Delveinsight

    Coronary Artery Disease Clinical Trial Space Intensifies with 20+ Companies in Active Development | DelveInsight

    The coronary artery disease treatment landscape is rapidly evolving with 20+ pharmaceutical companies actively developing 22+ pipeline drugs. Key players including Roche, Verve Therapeutics, Amgen, and others are advancing therapies targeting residual cardiovascular risk through novel mechanisms such as Factor XI inhibitors, gene therapy, and anti-inflammatory approaches. Recent clinical trial progress includes positive Phase IIa results for vortosiran and Phase II initiation of SRSD107, signaling growing momentum in addressing high-risk CAD patients beyond conventional treatments.

    RHHBYAMGN